Form 4: Arcutis Biotherapeutics Director Sells 10,000 Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares of common stock at a weighted average price of $12.5133 per share, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Howard G. Welgus, a director at Arcutis Biotherapeutics, sold 10,000 shares of the company's common stock.
- The sale occurred on December 2, 2024.
- The shares were sold at a weighted average price of $12.5133 per share.
- The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 5, 2024.
- The trading plan is set to end on May 30, 2025.
- The sale price ranged from $12.37 to $13.00 per share.
Sentiment
Score: 5
Explanation: The document reports a routine insider sale under a pre-arranged plan, which is neither positive nor negative. It's a neutral event.
Risks
- Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors. The use of 10b5-1 trading plans allows insiders to sell shares without being accused of trading on non-public information.
Comparison to Industry Standards
- Sales by directors are a normal part of the market, and the use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.
- The volume of shares sold is relatively small compared to the total outstanding shares of the company, so it is unlikely to have a significant impact on the stock price.
- Comparable companies in the biotech sector often see similar insider trading activity, with directors and officers selling shares for personal financial planning purposes.
Stakeholder Impact
- The sale may have a minor impact on shareholder sentiment, but it is unlikely to have a significant effect on the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 2024-03-05 | Date the 10b5-1 trading plan was adopted. |
| 2024-12-02 | Date of the stock sale transaction. |
| 2025-05-30 | End date of the 10b5-1 trading plan. |
| 2024-12-03 | Date the Form 4 was signed. |
Keywords
Arcutis Biotherapeutics, insider trading, Form 4, stock sale, Howard G. Welgus, 10b5-1 trading plan, ARQT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.